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Background: Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-
CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune
cancer therapy, many different agents have been used to mature DCs. We analyzed the kinetics of DC maturation
by lipopolysaccharide (LPS) and interferon-g (IFN-g) induction in order to characterize the usefulness of mature DCs
(mDCs) for immune therapy and to identify biomarkers for assessing the quality of mDCs.
Methods: Peripheral blood mononuclear cells were collected from 6 healthy subjects by apheresis, monocytes
were isolated by elutriation, and immature DCs (iDCs) were produced by 3 days of culture with GM-CSF and IL-4.
The iDCs were sampled after 4, 8 and 24 hours in culture with LPS and IFN-g and were then assessed by flow
cytometry, ELISA, and global gene and microRNA (miRNA) expression analysis.
Results: After 24 hours of LPS and IFN-g stimulation, DC surface expression of CD80, CD83, CD86, and HLA Class II
antigens were up-regulated. Th1 attractant genes such as CXCL9, CXCL10, CXCL11 and CCL5 were up-regulated
during maturation but not Treg attractants such as CCL22 and CXCL12. The expression of classical mDC biomarker
genes CD83, CCR7, CCL5, CCL8, SOD2, MT2A, OASL, GBP1 and HES4 were up-regulated throughout maturation
while MTIB, MTIE, MTIG, MTIH, GADD45A and LAMP3 were only up-regulated late in maturation. The expression of
miR-155 was up-regulated 8-fold in mDCs.
Conclusion: DCs, matured with LPS and IFN-g, were characterized by increased levels of Th1 attractants as
opposed to Treg attractants and may be particularly effective for adoptive immune cancer therapy.
Introduction
Dendritic cells (DC) are key players in both innate and
adaptive immune responses. They are potent antigen pre-
senting cells that recognize, process, and present antigens
to T-cells in vivo [1-3]. Consequently, DC-based immu-
notherapy has become one of the most promising
approaches for the treatment of cancer [4,5]. The fre-
quency of DCs in the peripheral blood is naturally low
and they are difficult to separate from other peripheral
blood leukocytes [6], therefore, to enhance DC function,
hematopoietic progenitor cells or peripheral blood
monocytes are usually used to produce mDC in vitro by
culture with growth factors and cytokines [6,7].
Large quantities of mononuclear cells can easily be
collected from the peripheral blood by leukapheresis.
Monocytes can be isolated from other leukocytes col-
lected by apheresis with high purity by adherence, elu-
triation, or using immunomagnetic beads [8-10]. To
produce immature DCs (iDCs), monocytes are usually
incubated with granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) and interleukin-4 (IL-4). Because
mature DCs (mDCs) are superior to iDCs for the stimu-
lation of cytotoxic T-cells, iDCs derived from monocytes
are often treated with various exogenous stimuli known
to induce DCs maturation including lipopolysaccharide
(LPS) and interferon-g (IFN-g) [5,11]. One of the goals
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changes associated with LPS and IFN-g induced DC
maturation to estimate the effectiveness of these mDCs
in adoptive immune cancer therapy.
When developing cellular therapies such as mDCs it is
often necessary to compare products manufactured with
a standard method and an alternative method. It is also
necessary to determine if products manufactured from
the starting material of different people are consistent
or similar. Once the manufacturing process has been
established and clinical products are being manufac-
tured, clinical cellular therapies must also be assessed
for potency. Another goal of this study was to identify
molecular biomarkers that were associated with DC
maturation and in order to characterize mDCs and that
could be used for consistency, comparibility, and
potency testing.
DCs are often assessed by flow cytometry for the
expression of the costimulatory molecules CD80 and
CD86, the maturation marker CD83, the chemokine
receptor CCR7, and antigen presentation molecules,
HLA class II antigens, to document the transition of
iDCs to mDCs. Some cellular therapy laboratories
also test the function of DCs by measuring their abil-
ity to produce IL-12, IL-10, IL-23 or IFN-g following
stimulation. However, the diverse functions of DC
therapies indicate that additional biomarkers are
necessory to characterize mDCs. Based on the multi-
ple functions of DCs and their broad spectrum of
effector molecules, it is highly improbable that a lim-
ited number of biomarkers can adequately measure
DC potency. But whole transcriptome expression ana-
lysis and microRNA (miR) profiling analysis of the
DC maturation process could provide better insight
into DC biology and identify biomarkers that are indi-
cators of DC potency.
Although monocytes, iDCs, and mDCs have been
characterized at a molecular level, few studies have com-
prehensively studied the molecular events associated
with DC maturation. In this study we compared the
kinetics of global changes of both gene and miR expres-
sion associated with LPS and IFN-g induced DC matura-
tion. Gene and miR changes in DCs were assessed after
4, 8 and 24 hours of LPS and IFN-g stimulation. To vali-
date the functional activity of DCs, we also tested solu-
ble protein production in culture supernatant after 24
hours of maturation and after incubation with CD40
ligand transfected mouse fibroblasts.
Materials and methods
Study design
Peripheral blood mononuclear cell (PBMC) concen-
trates were collected using a CS3000 Plus blood cell
separator (Baxter Healthcare Corp., Fenwal Division,
Deerfield, IL) from 6 healthy donors in the Depart-
ment of Transfusion Medicine (DTM), Clinical Center,
National Institutes of Health (NIH). All donors signed
an informed consent approved by a NIH Institutional
Review Board. Monocytes were isolated from the
PBMC concentrates on the day of PBMC collection by
elutriation (Elutra®, Gambro BCT, Lakewood, CO)
using the instrument’s automatic mode according to
the manufacturer’s recommendations. The monocytes
were treated with GM-CSF (2000 IU/mL, R&D Sys-
tems, Minneapolis, MN) and IL-4 (2000 IU/mL, R&D
Systems) for 3 days to produce iDCs. The iDCs were
then treated for 24 hours with LPS and IFN-g to pro-
duce mDCs. The results of analysis of iDCs and mDCs
by flow cytometry and gene expression profiling have
been previously published [12].
DC preparation, maturation, and harvest
The elutriated monocytes from each donor were sus-
pended at 6.7 × 10
6/mL with RPMI 1640 (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal calf serum
(FSC) (Invitrogen), 2 mM L-glutamine (Invitrogen), 1%
nonessential amino acids (Invitrogen), 1% pyruvate
(Invitrogen), 100 units/mL penicillin/streptomycin (Invi-
trogen), and 50 μM 2-mercaptoethanol (Sigma, St
Louis, MO). A total of 10 mL of monocyte suspension
was cultured in T25 culture flasks (Nalge Nunc Interna-
tional, Rochester, NY) overnight in a humidified incuba-
tor with 5% CO2 at 37°C. On Day 1, 2000 IU/mL
human IL-4 (R&D Systems) and 2000 IU/mL GM-CSF
(R&D Systems) were added to the culture. On Day 3,
an additional 2000 IU/mL IL-4 and GM-CSF were
added. To induce DC maturation, on day 4, 100 ng/mL
LPS (Sigma) and 1000 IU/mL IFN-g (R&D Systems)
were added. The DCs were harvested at 0, 4, 8 and 24
hours (h) after the addition of LPS and IFN-g.T o
remove the adherent DCs, 2 mM EDTA-PBS was added
to each flask on ice. The harvested cells were pelleted,
washed twice with HBSS, and resuspended in RPMI
1640. The total number of cells harvested and their via-
bility was measured microscopically after adding Trypan
Blue.
Flow cytometeric analysis
The purity of the elutriated monocytes was evaluated by
flow cytometry using CD14-P E ,C D 1 9 - F I T C ,C D 3 - P E -
Cy5, and CD56-APC (Becton Dickinson, Mountain
View, CA) and isotype controls (Becton Dickinson). To
confirm the maturation of the DCs, the harvested DCs
were tested with CD80-FITC, CD83-PE, CD86-FITC,
HLA-DR-PE-Cy5, and CD14-APC (Becton Dickinson)
and isotype controls (Becton Dickson). Flow cytometry
acquisition and analysis were performed with a FACS-
can using CellQuest software (Becton Dickinson).
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To measure DC cytokine production, iDC and mDCs
(100,000 cells/ml) were co-incubated with 50,000 cells/
ml of adherent mouse fibroblasts transfected to express
human CD40-Ligand (CD40L-LTK) in 48-well plates.
This cell line was kindly provided by Dr. Kurlander
(Department of Laboratory Medicine, Clinical Center,
National Institutes of Health, Bethesda, MD). Before (0
hour) and after 24 hours of stimulation the supernatant
was collected and the samples were analyzed by protein
expression profiling. The levels of 50 soluble factors
were assessed on an ELISA-based platform consisting of
multiplexed assays that measured up to 16 proteins per
well in standard 96 well plates (Pierce Search Light Pro-
teome Array, Boston, MA)[13].
RNA preparation, amplification, and labeling for
oligonucleotide microarray analysis
Total RNA was extracted from the DCs using Trizol
(Invitrogen, Carlsbad, CA). RNA integrity was assessed
using an Agilent 2100 Bioanalyser (Agilent Technolo-
gies, Waldbronn, Germany). Total RNA (3 μg) from the
DCs was amplified into anti-sense RNA (aRNA). While
total RNA from PBMCs pooled from the 6 normal
donors was extracted and amplified into aRNA to serve
as the reference. Pooled reference and test aRNA were
isolated and amplified using identical conditions and the
same amplification/hybridization procedures to avoid
possible interexperimental biases. Both reference and
test aRNA were directly labeled using ULS aRNA Fluor-
escent Labeling kit (Kreatech, Amsterdam, Netherlands)
with Cy3 for reference and Cy5 for test samples.
Human oligonucleotide microarrays spanning the
entire genome were printed in the Infectious Disease and
Immunogenetics Section, DTM, Clinical Center, NIH
using a commercial probe set containing 35,035 oligonu-
cleotide probes, representing approximately 25,100
unique genes and 39,600 transcripts excluding control
oligonucleotides (Operon Human Genome Array-Ready
Oligo Set version 4.0, Huntsville, AL, USA). The design
of the probe set was based on the Ensemble Human
Database build (NCBI-35c), with full coverage of the
NCBI human Reference sequence dataset (April 2, 2005).
The microarray was composed of 48 blocks with one
spot printed per probe per slide. Hybridization was car-
ried out in a water bath at 42°C for 18 to 24 hours and
the arrays were then washed and scanned on a GenePix
scanner Pro 4.0 (Axon, Sunnyvale, CA) with a variable
photomultiplier tube to obtain optimized signal intensi-
ties with minimum (<1% spots) intensity saturation.
miR expression analysis
A miRNA probe set was designed using mature anti-
sense miRNA sequences (Sanger data base, version 9.1)
consisting of 827 human, mouse, rat and virus probes
plus two control probes. The probes were 5’ amine
modified and printed in duplicate in the Immunoge-
netics Section of the DTM on CodeLink activated slides
(General Electric, GE Health, NJ, USA) via covalent
bonding. 3 μg total RNA was directly labeled with miR-
CURY™ LNA Array Power Labeling Kit (Exiqon) accord-
ing to manufacturer’s procedure. The total RNA from
Epstein-Barr virus (EBV)-transformed lymphoblastoid
cell line was used as the reference for the miRNA
expression assay. The test samples were labeled with
Hy5 and the references with Hy3. After labeling, both
the sample and the reference were co-hybridized to the
miRNA array at room temperature overnight and the
slides were washed and scanned by GenePix scanner
Pro 4.0 (Axon, Sunnyvale, CA, USA).
Data processing and statistical analyses
The raw data set was filtered according to a standard
procedure to exclude spots below a minimum intensity
that arbitrarily was set to an intensity parameter of 200
for the oligonucleotide arrays and 100 for the miR
arrays in both fluorescence channels. If the fluorescence
intensity of one channel was great than 200 for oligonu-
ceotide array (100 for miR array), but the other was
below 200(100), the fluorescence of the low intensity
channel was arbitrarily set to 200(100). Spots with dia-
meters <20 μm from oligonucleotide arrays, <10 μm
from microRNA arrays and flagged spots were also
excluded from the analysis. The filtered data was then
normalized using the median over the entire array and
retrieved by the BRB-ArrayTools http://linus.nci.nih.gov/
BRB-ArrayTools.html which was developed at the
National Cancer Institute (NCI), Biometric Research
Branch, Division of Cancer Treatment and Diagnosis.
Hierarchical cluster analysis and TreeView software
were used for visualization of the data [14,15]. Gene
annotation and functional pathway analysis was based
on the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) 2007 software [16] and Gen-
eCards website http://www.genecards.org/index.shtml.
miR and gene expression analysis by quantitative PCR
To validate the results of the microarray analysis, three
miR and 4 genes were selected for analysis by quantitive
real-time/reverse-transcription polymerase chain reaction
(RT-PCR). miR expression was measured and quantified
by TaqMan MicroRNA Assays (Applied Biosystems, Fos-
ter City, CA). Quantitative RT-PCR for miR-146a, miR-
146b, and miR-155 were performed according to the
manufacturer’s protocol and normalized by RNU48
(Applied Biosystems). Gene expressions for HLA-DRA
(Assay ID Hs00219578_m1), HLA-DRB1 (Assay ID
Hs99999917_m1), CCR7 (Assay ID Hs99999080_m1),
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by TaqMan Gene Expression Assays (Applied Biosys-
tems) according to manufacturers’ protocol and normal-
ized by GAPDH (Assay ID Hs99999905_m1). Differences
in expression were determined by the relative quantifica-
tion method; the Ct values of the test genes were normal-
ized to the Ct values of endogenous control GAPDH.
The fold change or the relative quantity (RQ) was calcu-
lated based on RQ = 2
-ΔCt,w h e r eΔCt = average Ct of
test sample - average Ct of endogenous control sample.
Results
Changes in DC antigen expression
Immature DCs were produced from peripheral blood
monocytes from 6 healthy subjects by stimulation with
GM-CSF and IL-4 for 3 days. The iDCs were further sti-
mulated with LPS and IFN-g and the expression of sur-
face markers CD80, CD83, CD86, and HLA-DR were
analyzed by flow cytometry before and after 4, 8, and 24
hours of LPS and IFN-g stimulation. The expression of
all 4 antigens increased during maturation (Table 1).
Kinetics of the gene expression changes during DC
maturation
Global gene expression was assessed in DCs from the 6
subjects pre-treatment (time 0, iDCs) and after 4, 8
and 24 hours of LPS and IFN-g stimulation. A total of
2,370 genes differed significantly among the matura-
tion time groups (F-test; p < 0.001). Supervised hier-
archical clustering revealed distinct clusters of genes
that characterized each of the maturation times
(Figure 1). Genes in clusters 1 and 2 were up-regulated
during maturation and those in clusters 3, 4, and 5
were down-regulated. At hours 4 and 8, genes in clus-
ter 1 were up-regulated compared to iDCs but
returned to base levels after 24 hours. Cluster 2 genes
were up-regulated on hours 4 through 24 of matura-
tion. Cluster 3 and 4 genes were down-regulated on
hours 4 and 8 but then returned to baseline levels
after 24 hours. However the level of expression of
genes in cluster 4 was greater after 24 hours than
those in cluster 3. After 4 hours the expression of
genes in cluster 5 were similar to baseline levels, but
were then down-regulated on hours 8 and 24.
Canonical pathway analysis showed that genes in each
of these 5 clusters belong to different pathways (See addi-
tional file 1, table S1). Genes in Clusters 1 and 2 were
most likely to be in pathways involved with the cellular
immune response (See additional file 1, table S1, bold
and *), cytokine signaling (See additional file 1, table S1,
italics and #), transcriptional regulation and the inflam-
matory response. This is consistent with cells that are
ready to respond or are already responding to external
stimuli. In contrast, genes in Clusters 3 and 4 were most
likely to belong to pathways involved with metabolism
(See additional file 1, table S1, bold and †). Genes in
Cluster 5 also belonged to metabolism pathways as well
as Humoral Immune Response and Pathogen-Influenced
Signaling Pathways (See additional file 1, table S1, italics
and $). The specific genes that were differentially
expressed among the DCs stimulated with LPS and IFN-g
for different durations of time and their fold-changes are
summarized in Tables S2 and S3 [see Additional Files 2
and 3] (t-test, p ≤ 0.001 compared to hr 0).
The genes up-regulated during DC maturation
included many involved with immune function, cell dif-
ferentiation, and migration. Several chemokines and their
ligands were up-regulated during maturation. For exam-
ple CCR7, which enhances the ability of DCs to migrate
to lymphoid nodes was markedly up-regulated during
maturation. Its expression was increased more than 10-
fold at all times during maturation and was greatest after
24 hours of maturation (up-regulated 18-fold). Moreover,
the expression of Oncostatin M (OSM), which enhances
the expression of the CCR7 ligand CCL21 by microvas-
cular endothelial cells and increases the efficiency of den-
dritic cell trafficking to lymph nodes [17], was increased
5- to 6-fold during maturation. In addition, CXCR4, a
chemokine receptor involved with DC migration to lym-
phoid nodes, was up-regulated 3-fold after 24 hours of
maturation [18]. However, the expression of several
inflammatory chemokine receptors including CCR1 and
CCR2 fell during maturation.
The expression of inflammatory chemokine ligands
including CCL2 (MCP-1), CCL3 (MIP1a), CCL4 (MIP1b),
CXCL1 (GROa) and CXCL9, reached a peak at 4 hours of
maturation but then rapidly returned to baseline levels.
However, the expression of chemokines CCL5 (RANTES),
Table 1 Comparison of DC expression of CD14, CD80, CD83, CD86, and HLA-DR antigens according to maturation time
Percent of DCs expressing each antigen*
Maturation Time CD80 CD83 CD86 CD83 & CD86 HLA-DR CD14
0 h 29.2 ± 9.5 36.6 ± 11.9 26.0 ± 13.2 20.8 ± 14.5 80.6 ± 10.3 0.22 ± 0.11
4 h 47.6 ± 16.9 67.4 ± 14.6 82.8 ± 6.3 69.0 ± 7.8 93.7 ± 3.6 0.18 ± 0.17
8 h 79.3 ± 12.7 80.0 ± 11.5 90.9 ± 6.2 81.6 ± 13.3 95.6 ± 2.2 0.19 ± 0.14
24 h 89.6 ± 7.5 93.8 ± 6.3 96.7 ± 1.8 97.8 ± 0.6 98.2 ± 1.1 0.10 ± 0.07
*Values represent the mean ± 1 standard deviation
h = hours
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sustained high expression levels through 24 hours. Chemo-
kine ligands that were part of Toll-like receptor signaling
pathways, such as CCL3, CCL4, CCL5, CXCL9 (MIG),
CXCL10 (IP-10), and CXCL11 (ITAC), were all up-regu-
lated more than 7-fold during maturation. The levels of
most of these genes peaked at hour 4 except for CCL5 and
CXCL10 which peaked at hour 8 and sustained high levels
of expression through hour 24. Chemokine ligands that
preferentially attract Th1 T cells such as CXCL9, CXCL10,
and CXCL11 were also markedly increased after 4 hours.
However, two chemokine ligands for CCR4, which are
important attractants of Th2 cells CCL17 (TARC) and
CCL22 (MDC), were only slightly up-regulated or showed
no significant change after 24 hours of maturation.
The expression of proinflamatory cytokines such as IL-1b
(IL-1B), IL-6, IL-8, IL-15, and TNF were up-regulated more
than 10-fold and their expression reached a peak after 4
hours. The expression of IL-12p40 (IL12B), IL-10 and IL-
27 were up-regulated less than 10-fold after 4 hours of
m a t u r a t i o na n dr e m a i n e da tt h es a m el e v e la f t e r2 4h o u r s .
The costimulatory molecules, CD80 and CD86, and
maturation marker CD83, all classic DC surface mar-
kers, were up-regulated durning DC maturation [see
Additional File 2, Table S2]. The expression of all three
was above baseline levels throughout maturation. The
expression of CD83 was markedly increased, 17- to 23-
fold, compared to 1.3- to 3.5-fold for CD80 and CD86.
Genes encoding the major histocompatibility complex
(MHC) Class I molecules (HLA-A, B, C, F, G, and H), pro-
teosome activator subunit 2 (PSME2), and antigen peptide
transport 1-2 (TAP1, 2) which are important for antigen
processing and presentation were all up-regulated more
than 2-fold through the 24 hours of maturation(see addi-
tional file 2, table S2). Interestingly, MHC Class II genes
were down-regulated during maturation, although analysis
by flow cytometry showed that the expression cell surface
HLA-DR protein increased during maturation (Table 1).
The transcription factor RelB, which is essential for
the development and function of DCs, was up-regu-
l a t e da p p r o x i m a t e l y3 - f o l da t4a n d8h o u r so fm a t u r a -
tion and 6-fold after 24 hours. This transcript factor
Figure 1 Gene expression changes in maturing DCs. Immature DCs from 6 healthy subjects were incubated with LPS and IFN-g. After 0, 4, 8,
and 24 hours of culture, DCs were analyzed by gene expression profiling using a microarray with 35,035 oligonucleotide probes. The 2,370
differentially expressed genes (F-test: p < 0.001) were analyzed by supervised hierachical clustering. Immature DCs are indicated by the orange
bar, iDCs cultured with LPS and IL-4 for 4 hours by the green bar, 8 hours by the purple bar, and 24 hours by the red bar. The genes sorted into
5 separate clusters and representive genes from each of the 5 clusters are shown.
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loid DCs rather than to macrophages. Another family
of transcription factors which are involved in DC dif-
ferentiation and function are the Interferon regulatory
factors (IRFs). Two members of this family are espe-
cially important, IRF4 and IRF8, and both were up-
regulated during DC maturation. SOCS1 (Suppressors
of cytokine signaling 1) which has been shown to play
a major role in regulation DC was increased 1.6-fold
after 4 hours and SOCS2 expression was increased 4.8-
to 5.7-fold throughout maturation(see additional file 2,
table S2).
The expression of some genes was greatest in mDCs.
Among these genes, two involved with antigen presenta-
tion, LAMP3 and MARCKSL1, were up-regulated 4 hours
after LPS and IL-4 stimulation and their expression con-
tinued to increase throughout the study period. The maxi-
m u mc h a n g ei ne x p r e s s i o no fL A M P 3a n dM A R C K S L 1
were observed after 24 hours of maturation with a 37-fold
and 21-fold increase respectively. The expression of the
cell cycle and cell signaling genes GADD45A and RGS1
also increased most after 24 hours of maturation. Their
expression peaked with 50-fold and 28-fold up-regulation
respectively(see additional file 2, table S2).
Genes that were down-regulated during DC matura-
tion included CD1C, CD33 and CD14. CD14 was only
down-regulated 1.5- to 2.0-fold during the 24 hour per-
iod, but CD33 was down-regulated 6- to 64-fold and
CD1C was down-regulated 57- to 81-fold (see additional
file 3, table S3).
To validate the microarray results, 4 genes (HLA-DRA,
HLA-DRB1, CCR7, and CD86) were selected for analysis
by quantitive RT-PCR. HLA-DRA and HLA-DRB1 were
selected because although the expression of HLA Class II
antigens are increased in mDCs, microarray analysis
found that the expression HLA-DRA and HLA-DRB1
were down-regulated. CCR7 and CD86 were selected
because microarray analysis showed that the expression
of both genes were up-regulated during DC maturation.
In addition, CCD7 is an important chemotaxis receptor
and CD86 and important costimulatory molecule. The
results from quantitive RT-PCR were consistent from
those obtained with the microarrays (Figure 2).
miR expression during DC maturation
The expression of miR was also measured during DC
maturation. Among the 474 miR analyzed 57 were dif-
ferentially expressed (F-test, p ≤ 0.05) and were pre-
sent in more than 80% of the samples. Hierarchical
cluster analysis separated the samples into 2 major
groups; an early group which included DCs samples
treated with LPS and IFN-g for 0 and 4 hours and a
late group which containing DC samples treated with
LPS and IFN-g for 8 and 24 hours (Figure 3). Both the
early and late groups contai n e dt w os u b g r o u p s .T h e
samples in these four subgroups were separated
according to maturation time; hours 0, 4, 8 and 24. In
contrast to gene expression, where several patterns or
w a v e so fe x p r e s s i o nw e r en o t e d ,o n l yt w og e n e r a lp a t -
terns were noted for miR analysis: miR whose expres-
sion decreased with maturation and miR whose
expression increased with maturation. Compared with
iDC, miR-155, miR-605, miR-146a, miR-146b, miR-
623, miR-583, miR-26a, miR-519d, miR-126, and miR-
7 were significantly up-regulated in mDC. miR-155
was up-regulated the most (8-fold) after 24 hours. The
other miRs were up-regulated 1.5- to 1.76-fold. miR-
375, miR-451, miR-593, miR-555, and miR-134 were
down-regulated significantly (2.3- to 2.9-fold) after 24
hours (Table 2).
To validate the miR microarray results, miR-146a,
miR-146b, miR-155, were selected for analysis by quan-
titative RT-PCR. These miR was selected because they
have been previously found to be expressed by macro-
phages or DCs [19-21]. The results were consistent with
those obtained with the microarrays (Figure 4).
Proteins Produced during DC maturation
The levels of 50 proteins were measured in DC culture
supernatants at time 0 and after 24 hours of maturation.
The proteins whose levels changed significantly (t-tests,
p<0 . 0 5 )w e r ev i s u a l i z e db yah e a t m a p( F i g u r e5 ) .T h e
levels of 16 proteins related to the DC function
increased including CXCL1 (GROa), CCL2 (MCP1),
CCL3 (MIP1a), CCL4 (MIP1b), CCL5 (RANTES), CCL8
(MCP2), CCL11 (Eotaxin), CCL17 (TARC), CCL22
(MDC), CXCL9 (MIG), CXCL10 (IP10), CXCL11
( I T A C ) ,I L - 6 ,I L - 8 ,I L - 1 0 ,I L - 1 2a n dT N F - a [see Addi-
tional File 4, Table S4]. These results are consistent
with the changes in gene expression levels.
Mature DC function testing and cytokine detection
To test the function of ma t u r eD C s ,w ei n c u b a t e d
mDCs with mouse fibroblasts transfected to express
human CD40-Ligand (CD40L-LTK) and compared
supernatant factor levels in CD40L-LTK-stimulated
mDCs with unstimulated mDCs. The levels of two
important cytokines related to DC function, IL-12 and
IL-10, increased more than 20-fold post-stimulation
(Figure 6). We also observed that the levels of cytokines
and chemokines involved in regulating inflammatory
and immune responses were elevated. These factors
included: IL-1b, IL-2, IL-5, IL-6, IL-13, IL-23, IL-1b,
IFN-g,T N F - a, CCL3 (MIP1a), CCL4 (MIP1b), CCL5
(RANTES), CXCL9 (MIG), CXCL10 (IP10), and
CXCL11 (ITAC) [see Additional File 5, Table S5]. These
findings are consistent with the results of result of gene
expression profiling.
Jin et al. Journal of Translational Medicine 2010, 8:4
http://www.translational-medicine.com/content/8/1/4
Page 6 of 15Discussion
The use of DC-based cellular therapies to enhance
innate and adoptive immune mediated tumor rejection
is a very promising regimen which has shown evidence
of improving patient survival and objectively enhancing
tumor elimination. Numerous DC maturation protocols
have been developed and each one has unique features
to enhance DC function. In this study, we used a classi-
cal iDC generation procedure that makes use of GM-
CSF plus IL-4 stimulation which was followed by LPS
plus IFN-g maturation. We studied changes in gene and
miR expression in maturing DCs to characterize the nat-
ure of the mDCs produced with LPS and IFN-g and to
identify genes and miR that could serve as biomarkers
for the characterization mDCs
Our study demonstrated that after 24 hours of stimu-
lation with LPS and IFN-g, mDCs expressed increased
levels of HLA Class I and Class II antigens as well as
the costimulatory molecules CD80, CD86 and the che-
motaxic receptor CCR7. The mDCs were also well-
armed to induce Th1 responses as exemplified by signif-
icant elevations in the expression of the Th1 cell attrac-
tants CXCL9, CXCL10, CXCL11 and CCL5. Another
factor used for DC maturation, prostaglandin E2
(PGE2), induces mDCs which produced high levels of
the regulator T cell (Treg) attracting cytokines CCL22
and CXCL12 [22]. These Treg cells can counter the
effects of Th1 responses by cytotoxic T cells, Th1 cells,
and NK cells. In contrast, we found that LPS and IFN-g
maturated DCs did not increase the levels of CCL22
and CXCL12 expression.
We found that the expression of a number of other
genes were up-regulated during DC maturation. The
up-regulated genes during DC fell into three general
categories: those that were up-regulated to a similar
level throughout maturation, those that were most up-
Figure 2 Change in the expression of CCR7, CD86, HLA-DRA, and HLA-DRB during DC maturation. iDCs from 6 healthy subjects sampled
after 0, 4, 8 and 24 hours of culture in LPS and IFN-g were analyzed by quantitive RT-PCR for the expression of CCR7, CD86, HLA-DRA, and HLA-
DRB.
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Page 7 of 15regulated early in maturation and those that were most
up-regulated after 24 hours of maturation. Genes whose
expression was up-regulated throughout maturation
were most likely to belong to several pathways involved
with inflammation: interferon signaling, IL-10 signaling,
CD40 signaling, IL-6 signaling, activation of IRF by cyto-
solic pattern recognition receptors and role of pattern
recognition receptors in recognition of bacteria and
virus pathways. Specific genes that were up-regulated
throughout maturation include CCL3, CCL4, CCL5,
CCL8, CXCL10, CXCL11, CCR7, IL-1b, IL-6, IL-15, IL-
27, IL-7R, IL-10RA, IL-15RA, STAT1, STAT2, STAT3,
CD80, CD83, and CD86. Among the genes that were
markedly up-regulated (more than 10-fold) during
maturation and are good potential mDC biomarkers are
C C L 5 ,C X C L 1 0 ,C C R 7 ,I F I 4 4 L ,I F I H 1 ,M X 1 ,I S G 1 5 ,
ISG20, INDO, MT2A, TRAF1, BRIC3, USP18, and
CD83 (Table 3). CCL5, CCR7, and CD83 may be parti-
cularly good potency biomarker candidates because they
have important roles in DC function.
Genes whose expression was most up-regulated early
in maturation included genes in the NF-kB signaling;
IL-6, IL-8, IL-10, IL-15 and IL-17 signaling; 4-1 bb sig-
naling in T lymphocytes; MIF regulation of innate
immunity; and role of pattern recognition receptors in
the recognition of bacteria and viruses pathways.
Figure 3 miR expression changes in maturing DCs. Immature DCs from 6 healthy subjects were incubated with LPS and IFN-g and after 0, 4,
8, and 24 hours of culture, they were analyzed by global microRNA expression profiling using a microarray with 827 probes. The differentially
expressed human miR (F-test: p < 0.05) were analyzed by supervised hierachical clustering. The samples clustered into 4 groups based on
maturation time, iDC are indicated by the green bar, DCs cultured for 4 hours by the orange bar, DCs cultured for 8 hours by the red bar, and
24 hours by the purple bar. The miRs sorted into 2 separate clusters and miRs from each of the clusters are shown.
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Page 8 of 15Table 2 MicroRNA (miRNA) whose expression changed in iDCs following LPS and IFN-g stimulation (T-test, p ≤ 0.05)
Up-regulated MicroRNA Down-regulated MicroRNA
Fold Increase Fold Decrease
MicroRNA 4 h 8 h 24 h MicroRNA 4 h 8 h 24 h
hsa-miR-155 3.29 4.65 8.01 hsa-miR-375 -1.75 NS -2.9
hsa-mir-605 NS 1.45 1.76 hsa-miR-451 -2.3 NS -2.76
hsa-miR-146a 1.27 1.45 1.73 hsa-mir-593 -1.79 -1.85 -2.43
hsa-mir-623 5.59 NS 1.72 hsa-mir-555 -1.68 -1.82 -2.37
hsa-miR-146b NS 1.43 1.7 hsa-miR-134 NS -1.56 -2.29
hsa-mir-583 NS NS 1.59 hsa-miR-200b -1.57 -1.47 -1.83
hsa-miR-26a NS NS 1.58 hsa-miR-122a -1.45 -1.63 -1.83
hsa-miR-519d NS NS 1.54 hsa-miR-452 -1.49 NS -1.79
hsa-miR-126 NS NS 1.53 hsa-miR-215 -1.4 NS -1.72
hsa-miR-7 NS 1.35 1.51 hsa-mir-644 NS NS -1.7
hsa-let-7b NS 1.29 1.49 hsa-miR-504 -1.73 -1.25 -1.67
hsa-miR-370 NS 1.19 1.48 hsa-miR-499 NS NS -1.65
hsa-let-7a NS 1.35 1.48 hsa-miR-335 -1.32 NS -1.61
hsa-let-7i NS 1.2 1.48 hsa-mir-554 NS NS -1.59
hsa-miR-30a-3p NS NS 1.47 hsa-miR-422a -1.37 -1.43 -1.58
hsa-mir-565 2.43 1.99 1.46 hsa-miR-383 -1.42 -1.45 -1.57
hsa-let-7e NS NS 1.46 hsa-miR-138 NS NS -1.54
hsa-mir-598 1.74 1.68 1.45 hsa-miR-206 -1.33 -1.38 -1.53
hsa-mir-594 NS NS 1.44 hsa-mir-552 -1.35 -1.51 -1.53
hsa-let-7c NS NS 1.44 hsa-miR-325 NS NS -1.53
hsa-miR-212 NS 1.22 1.43 hsa-miR-517* -1.46 -1.38 -1.5
hsa-let-7d NS NS 1.43 hsa-miR-422b -1.37 NS -1.47
hsa-miR-331 NS NS 1.43 hsa-miR-10b NS NS -1.46
hsa-mir-657 NS NS 1.42 hsa-miR-130a -1.44 -1.38 -1.45
hsa-miR-487a NS 1.25 1.42 hsa-mir-597 NS NS -1.44
hsa-mir-611 1.48 1.61 1.42 hsa-miR-130b -1.28 -1.26 -1.43
hsa-mir-596 1.26 1.36 1.4 hsa-mir-580 NS NS -1.42
hsa-miR-361 NS NS 1.4 hsa-miR-33 NS NS -1.41
hsa-let-7d NS NS 1.38 hsa-miR-526a -1.88 NS -1.4
hsa-miR-24 NS 1.42 1.38 hsa-mir-634 -1.36 NS -1.4
hsa-mir-181d NS 1.37 1.37 hsa-mir-651 NS NS -1.38
hsa-miR-302c* 1.33 1.54 1.36 hsa-mir-765 NS NS -1.36
hsa-mir-769 NS NS 1.36 hsa-miR-100 NS NS -1.36
hsa-mir-421 NS 1.28 1.35 hsa-mir-770 NS NS -1.34
hsa-miR-500 NS NS 1.35 hsa-miR-192 NS NS -1.33
hsa-let-7g NS NS 1.34 hsa-miR-363* NS NS -1.33
hsa-miR-377 NS NS 1.33 hsa-miR-510 -1.39 -1.39 -1.32
hsa-mir-768 1.31 NS 1.33 hsa-miR-488 -1.18 NS -1.32
hsa-mir-650 NS 1.29 1.31 hsa-miR-214 NS NS -1.31
hsa-miR-485-5p NS NS 1.3 hsa-mir-617 NS NS -1.3
hsa-mir-801 1.25 NS 1.29 hsa-miR-381 -1.33 -1.32 -1.3
hsa-mir-663 1.43 NS 1.29 hsa-miR-302b* NS NS -1.29
hsa-mir-591 NS 1.24 1.29 hsa-mir-635 NS -1.37 -1.28
hsa-miR-433 NS NS 1.28 hsa-miR-518f* NS NS -1.28
hsa-mir-662 NS 1.28 1.28 hsa-mir-632 -2.03 NS NS
hsa-miR-409-3p NS 1.08 1.27 hsa-miR-128a -1.79 NS NS
hsa-miR-29b NS NS 1.26 hsa-mir-640 -1.68 -1.49 NS
hsa-miR-373* 1.33 1.28 1.26 hsa-miR-142-5p -1.52 NS -1.26
hsa-miR-378 NS NS 1.25 hsa-mir-610 -1.4 NS NS
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Page 9 of 15Table 2: MicroRNA (miRNA) whose expression changed in iDCs following LPS and IFN-g stimulation (T-test, p ≤ 0.05) (Continued)
hsa-mir-411 NS NS 1.25 hsa-miR-520a* -1.36 NS NS
hsa-mir-588 2.36 NS NS hsa-miR-133b -1.34 NS NS
hsa-mir-578 2.08 NS NS hsa-mir-628 -1.3 -1.26 NS
hsa-miR-492 1.34 NS NS hsa-miR-9* -1.29 NS NS
hsa-miR-221 1.32 NS NS hsa-miR-513 -1.27 -1.26 NS
hsa-mir-602 1.24 NS NS hsa-miR-185 -1.25 -1.22 NS
hsa-miR-328 1.2 NS NS hsa-miR-124a -1.24 NS NS
hsa-miR-502 1.2 NS NS hsa-miR-125b -1.23 -1.19 NS
hsa-mir-551b NS 1.86 NS hsa-miR-526a -1.23 NS NS
hsa-miR-340 NS 1.64 NS hsa-mir-376b NS -1.56 NS
hsa-mir-572 1.35 1.58 NS hsa-miR-412 NS -1.44 NS
hsa-miR-200a* NS 1.47 NS hsa-miR-10a NS -1.38 NS
hsa-mir-614 1.33 1.32 NS hsa-miR-193b NS -1.27 NS
hsa-miR-498 NS 1.32 NS hsa-miR-453 NS -1.24 NS
hsa-miR-222 NS 1.28 NS hsa-mir-584 NS -1.2 NS
hsa-miR-34b NS 1.25 NS hsa-mir-575 NS -1.2 NS
hsa-miR-27a NS 1.24 NS hsa-mir-582 NS -1.14 NS
hsa-mir-660 NS 1.24 NS
hsa-mir-675 NS 1.21 NS
hsa-mir-551a 1.2 1.17 NS
NS = not significant
Figure 4 Change in the expression of miR-146a, -146b, and -155 during DC maturation. iDCs from 6 healthy subjects sampled after 0, 4, 8
and 24 hours of culture in LPS and IFN-g were analyzed by quantitive RT-PCR for the expression of miR-146a, -146b, and -155.
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Page 10 of 15Specific genes that were most up-regulated early in
maturation include CXCL1, IL-1a,T N F ,T N F S F 8 ,
TNFAIP5, TNIP3, TRAF3, JAK2, BID, CASP1, LILRB1,
LILRB2, IILRB3, 2NF422, MMP-10, IL-10, and IL-12b.
Genes whose expression was markedly up-regulated
early and are good biomarker candidates include: CCL4
(MIP-1b), HES4, GBP1, OSAL, IFIT3, IL-8, IL7R, and
TNFAIP6 (Table 3).
The DC genes that were most up-regulated after 24-
hours of stimulation, in general, included genes that
belonged to metabolic pathways. However, a number of
inflammatory pathway genes were also in this group.
Genes in this group included CXCR4, IFITM4P,
I F I T M 1 ,G A D D 4 5 A ,L A M P 3 ,T R A F 5 ,S T A T 5 ,C A S P 3 ,
G Z M B ,M T I B ,M T I E ,M T I G ,M T I H ,C C L 8 ,H L A - A ,
HLA-B, HLA-C, and LYGE. Among these genes
GADD45A, MTIE, and MTIG were not up-regulated
after 4 hours, but were markedly up-regulated after 24
hours and may be especially good biomarker candidates
(Table 3).
Some genes were markedly down-regulated in mDCs
including CD1C, MAF, and CLEC10A (Table 4). These
Figure 5 Cytokine, chemokine and growth factors production by cultured DCs. The supernants from the 6 healthy subject iDCs and mDCs
from 6 healthy subjects were analyzed for 50 cytokines, chemokines and growth factors using an ELISA assay. The levels of 36 soluble factors
differed between iDCs and mDCs (t-tests, p < 0.05), the levels of all 36 were greater in mDCs. The differentially expressed factors were analyzed
by unsupervised hierachical clustering analysis.
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Page 11 of 15genes are also mDC biomarker candidates. The expres-
sion of MHC Class II genes was down-regulated during
maturation, but flow cytometer analysis showed that the
cell surface expression of HLA-DR protein increased
during maturation (Table 1). This observation suggests
an active regulation of these genes at the transcription
level. These transcripts could be sensored by the
encoded protein and regulatory miR. This observation
could also be explained by the fact that the majority of
MHC II molecules are stored intracellularly within the
internal vesicles of multivesicular bodies in iDCs. Thus
MHC II antigen expression can increase while gene
expression decreases.
Many cellular therapy laboratories use the produc-
tion of IL-10 and IL-12 as mDC potency assays. We
also found that the mDCs produced soluble IL-10 and
IL-12. However, the expression of the genes encoding
IL-10 and IL-12B(p40) were up-regulated 3- to 6-fold
after 4 and 8 hours of LPS and IFN-g stimulation, but
returned to baseline levels after 24 hours suggesting
that these genes may not be good molecular
biomarkers.
miRs are endogenously encoded regulatory RNA
which regulate mRNA by targeting their 3’UTR and
inducing mRNA degradation or protein translation sup-
pression. They are highly involved in development
Figure 6 Production of cytokine, chemokine and growth factors by stimulated mDCs. Mature DCs from 6 healthy subjects produced by
incubation with LPS and IFN-g were incubated with mouse fibroblasts transfected with CD40-Ligand (CD40L-LTK). The supernant from the
stimulated mDCs and unstimulated mDCs were analyzed for 50 cytokines, chemokines and growth factors using an ELISA assay. The levels of the
50 soluble factors were analyzed by unsupervised hierachical clustering analysis. The DCs separated into stimulated mDCs (purple bar) and
unstimulated mDCs (orange bar). The cluster of factors that were increased in stimulated mDCs are shown in the purple box and those
decreased in stimulated mDCs are shown in the orange box.
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Page 12 of 15timing, differentiation, and cell cycle regulation. To
understand how miR expression is involved in DC
maturation, we used miR array analysis. Unlike gene
expression analysis, miR expression analysis of maturing
DCs revealed two distinct patterns: down-regulation of
groups of miR at 8 hours of maturation with sustained
low expression throughout the rest of maturation and
up-regulation of other groups of miR at 8 hours of
maturation and sustained up-regulation. Among the up-
regulated miR, the best candidate for potency testing is
miR-155. The expression of miR-155 increased more
than any other miR with 3-fold up-regulation after 4
hours, 4-fold after 8 hours and 8-fold after 24 hours.
This finding is supported by previous reports that miR-
155 expression is increased in DC maturation [19-21].
Other miRs that may be good biomarkers are miR-146a
and miR-146b, which we also found were up-regulated
during DC maturation. These two miRs have also been
found to be up-regulated in DCs matured with IL-1b,
IL-6, TNFa and PGE2 [21].
Since miR control the expression of multiple genes
and proteins, they may actually be better biomarkers of
p o t e n c yt h e ns i n g l eg e n e so rp r o t e i n s .m i R - 1 5 5i s
located within the noncoding B cell integration cluster
(Bic) gene [23] and is functionally important in B cell, T
cell and macrophage biology. miR-155 is up-regulated in
B cells exposed to antigen, in T cells stimulated by Toll-
like receptor ligand and in macrophages by IFN-g stimu-
lation[24,25]. The Toll-like receptor/interleukin-1 (TRL/
IL-1) inflammatory pathway appears to be a general tar-
get of miR-155 [19]. One of the genes that it directly
targets is the DC transcription factor PU.1 [20]. Further-
more, miR-155 directly controls TAB2 a signal trans-
duction molecule. miR-155 may be part of a negative
feedback loop which down modules inflammatory cyto-
kine production including IL-1b in response to LPS-sti-
mulation [19]. Hence, miR-155 may be a particularly
good mDC potency biomarker.
The ability of these studies to identify mDC biomar-
kers is some what limited by the variability of methods
used to produce iDCs and mDCs among various labora-
tories. We used a 3 day DC differentiation protocol that
uses IL-4 and GM-CSF followed by differentiation with
LPS and IFN-g. This method is very similar to that used
in several clinical vaccine protocols involving mature
Table 3 Genes up-regulated during DC maturation that
could be used as biomarkers for assessing mDCs














Up-regulated to a similar degree
throughout maturation
Up-regulated most early in DC
maturation
aCCL5 108 148 94.1 IL6 13.1 11.3 5.15
CXCL10 28.5 31.8 21.2 IL8 78.0 70.3 12.7
CCR7 10.5 11.5 18.2 IL7R 29.1 29.9 10.5
IL15 7.12 5.54 8.13 CCL4 92.3 53.4 6.91
IFI27 6.99 7.62 10.2 TNFAIP6 30.0 18.7 10.7
IFI44L 14.8 16.7 20.5 IFIT3 36.2 22.5 10.5
IFIH1 16.9 9.42 11.3 OASL 68.1 44.1 30.7
IFIT1 29.8 27.0 21.7 GBP1 66.2 35.3 30.2
MX1 18.4 15.6 14.1 HES4 229 115 37.4
ISG15 50.6 58.3 41.8 Up-regulated most late in DC
maturation
ISG20 94.1 87.9 62.9 CCL8 11.3 31.8 31.2
IRF7 9.77 9.38 12.0 EBI3 17.6 21.8 34.6
GBP4 36.3 21.2 20.2 IFITM1 13.2 22.5 48.6
DUSP5 21.7 15.8 22.6 MT1B 10.2 10.5 20.6
NFKBIA 11.7 13.3 10.4 MT1E NS 1.78 46.1
ATF3 10.2 5.38 11.4 MT1G NS 2.77 42.3
TNFSF10 19.4 14.8 13.8 MT1H 22.7 20.5 62.6
TNFRSF9 8.13 6.39 10.2 GADD45A NS 11.6 50.7
SOD2 51.6 58.4 28.0 CD200 2.49 4.94 15.1
CD38 8.35 9.26 9.02 LAMP3 11.7 17.5 37.4
CD44 3.48 1.76 2.18 RGS1 5.70 18.1 28.3
CD80 3.14 2.93 3.49 SAT1 3.79 6.26 18.1
CD83 22.0 17.3 23.6 CYP27B1 6.59 12.5 21.4
CD86 1.62 1.32 2.34 RIPK2 10.7 14.0 23.1
INDO 28.6 18.6 16.3
MT2A 54.3 72.0 69.2
TRAF1 31.4 16.7 24.4
GADD45B 17.8 10.7 10.2
MT1M 8.26 8.40 15.1
MT1P2 14.6 13.9 20.3
BIRC3 23.0 18.4 28.2
USP18 34.7 29.9 29.8
TUBB2A 10.7 8.19 10.4
Fold-increase compared to iDCs.
Table 4 Genes down-regulated during DC maturation
that could be used as biomarkers for assessing mDCs
Fold decrease in gene expression for each
maturation time*
Gene 4 hours 8 hours 24 hours
Genes down-regulated to a similar degree throughout maturation
CD1C 64.0 82.2 57.8
MYC 9.17 8.83 9.35
MAF 15.0 8.30 20.5
PTGS1 5.43 20.4 13.0
DOK2 8.78 7.03 9.63
Genes down-regulated most late in DC maturation
TGFBI 2.44 6.76 11.2
GATM 2.70 12.0 17.7
ARHGDIB 2.37 10.1 15.4
MRC1 NS 7.15 30.22
CLEC10A 3.82 28.2 43.5
Fold-increase compared to iDCs.
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Page 13 of 15DCs. However, other protocols use 5 to 8 days of IL-4
and GM-CSF culture to produce iDCs and a variety of
other agents are being used for DC maturation. We also
used FCS rather than human AB serum in these studies
and this could have had some effects on DC
maturation.
In conclusion, we found that LPS and IFN-g induced
mDCs expressed large quantities of Th1 attractants, but
not Treg attractants, suggesting that these mDCs will be
particularly effective for adoptive immune cancer ther-
apy. In addition, we identified several genes and miRs
that may be useful biomarkers for consistency, compar-
ability, and potency testing. However, further studies are
needed to validate their utility as biomarkers.
Additional file 1: Table S1: The 30 canonical pathways with the
most differentially expressed DC genes for each of the 5 gene
clusters. Canonical pathway analysis showed that genes in each of these
5 clusters belong to different pathways.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-5876-8-4-
S1.DOC]
Additional file 2: Table S2. Immature DC Genes whose expression
was up-regulated following LPS and IFN-g stimulation. The specific
genes that were differentially expressed among the DCs stimulated with
LPS and IFN- g for different durations of time and their fold-change, up-
regulated genes summary. (t-test, p ≤ 0.001 compared to hr 0).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-5876-8-4-
S2.DOC]
Additional file 3: Table S3. Immature DC Genes whose expression
was down-regulated following LPS and IFN- g stimulation. The
specific genes that were differentially expressed among the DCs
stimulated with LPS and IFN- g for different durations of time and their
fold-change, down-regulated genes summary. (t-test, p ≤ 0.001
compared to hr 0).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-5876-8-4-
S3.DOC]
Additional file 4: Table S4. Soluble factor levels in DC cell culture
supernatant whose expression was up-regulated following LPS and
IFN- g stimulation. Soluble factor levels in DC cell culture supernatant
whose expression was up-regulated following LPS and IFN- g stimulation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-5876-8-4-
S4.DOC]
Additional file 5: Table S5. Soluble factor levels and fold changes in
mature DC culture supernatant after 24 hours of CD40 Ligand
stimulation. Soluble factor levels and fold changes in mature DC culture
supernatant after 24 hours of CD40 Ligand stimulation.
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